Search Results

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE).

As AAV9 and CRISPR programs navigate safety, delivery and scalability hurdles, small molecules offer a deployable, scalable bridge, complementing genetic approaches and accelerating meaningful impact for patients with Duchenne muscular dystrophy.

Eli Lilly and Company and DICE Therapeutics, Inc. announced a definitive agreement for Lilly to acquire DICE.

Eli Lilly stands to gain access to DICE Therapeutics’ DELSCAPE platform, which enables the design of orally available molecules for autoimmune and inflammatory diseases.

At Google Cloud’s second annual Cancer AI Symposium, Model Medicines will unveil how its GALILEO™ platform, built on Google Cloud, powered a 325 billion molecule throughput oncology screen — the largest of its kind — opening the door to trillion‑scale discovery and culminating in the discovery of MDL‑4102, a potent and selective BRD4 inhibitor.

DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today announced management will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 3:00 p.m. PT / 6:00 p.m. ET.